目的 分析芪血通絡(luò)片輔助治療糖尿病足潰瘍的臨床療效及安全性。方法 選擇2019年1月-2020年1月遼寧中醫(yī)藥大學(xué)附屬醫(yī)院收治的124例糖尿病足潰瘍患者作為研究對象，采用抽簽方法將患者分成對照組（62例）與觀察組（62例）。對照組患者均給予血糖控制、抗感染、機(jī)體微循環(huán)改善等綜合治療。觀察組在對照組基礎(chǔ)上口服芪血通絡(luò)片，4片/次，3次/d。所有患者均治療2個月。觀察兩組患者的臨床療效，同時比較兩組治療前后的病足潰瘍大小、糖代謝指標(biāo)（包括空腹血糖、餐后2 h血糖、糖化血紅蛋白）以及炎癥指標(biāo)（白細(xì)胞計數(shù)、超敏C-反應(yīng)蛋白、D-葡聚糖）等的變化情況。結(jié)果 治療后，對照組和觀察組總有效率分別為69.36%和85.48%，兩組對比差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者的病足潰瘍長徑、短徑均顯著縮短，差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組患者的病足潰瘍長徑、短徑均顯著短于對照組，兩組對比差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組空腹血糖、餐后2 h血糖、糖化血紅蛋白、白細(xì)胞計數(shù)、超敏C-反應(yīng)蛋白、D-葡聚糖均較治療前顯著降低，差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組的上述指標(biāo)水平均顯著低于對照組，對比差異有統(tǒng)計學(xué)意義（P<0.05）。兩組均未發(fā)生嚴(yán)重不良反應(yīng)。結(jié)論 芪血通絡(luò)片輔助治療糖尿病足療效顯著，能顯著縮小患者的潰瘍面積，控制患者血糖，改善患者炎癥癥狀，同時引發(fā)不良反應(yīng)少，安全性高，值得推薦。

Objective To analyze the efficacy and safety of Qixue Tongluo Tablets in treatment of diabetic foot ulcer. Methods A total of 124 patients with diabetic foot ulcer admitted to Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from January 2019 to January 2020 were selected as the research subjects. The patients were divided into control group (62 cases) and observation group (62 cases) by lotting. Patients in the control group were given integrated treatment of blood glucose control, anti-infection and microcirculation improvement. Patients in the observation group were po administered with Qixue Tongluo Tablets on the basis of control, 4 tablets/time, three times daily. All patients were treated for 2 months. The clinical efficacy of two groups was observed, and the changes in the size of foot ulcer, glucose metabolism indexes (including fasting blood glucose, blood glucose at 2 h postprandial, glycosylated hemoglobin) and inflammatory indexes (WBC count, hypersensitive C-reactive protein, Dglucan) before and after treatment were compared between two groups. Results After treatment, the total effective rate of the control group and the observation group was 69.36% and 85.48%, respectively, and there was statistical significance between two groups (P < 0.05). After treatment, the length diameter and short diameter of diseased foot ulcer in two groups were significantly shortened, with statistical significance (P < 0.05). The length diameter and short diameter of diseased foot ulcer in the observation group were significantly shorter than those in the control group, and the difference between the two groups was statistically significant (P < 0.05). After treatment, fasting blood glucose, 2 h postprandial blood glucose, glycated hemoglobin, white blood cell count, hypersensitive C-reactive protein, and D-glucan in two groups were significantly decreased compared with before treatment, with statistical significance (P < 0.05). The above indexes in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P < 0.05). No serious adverse reactions occurred in both groups. Conclusion Qixue Tongluo Tablets has significant efficacy in adjuvant treatment of diabetic foot, which can significantly reduce the ulcer area, control the blood sugar of patients, improve the inflammatory symptoms of patients, and cause fewer adverse reactions, with high safety, and is worthy of recommendation.

R977